Cutler Group LP Beam Therapeutics Inc. Call Options Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	SELL	$36.73 - $51.6 $55,094 - $77,400	-1,500 Reduced 93.75%	100 $0
Q3 2022 Oct 25, 2022	BUY	$39.79 - $70.31 $63,664 - $112,496	1,600 New	1,600 $2,000
Q3 2021 Oct 26, 2021	SELL	$84.37 - $133.6 $750,893 - $1.19 Million	-8,900 Closed	0 $0
Q2 2021 Jul 19, 2021	SELL	$64.12 - $128.71 $1.76 Million - $3.54 Million	-27,500 Reduced 75.55%	8,900 $182,000
Q1 2021 Apr 26, 2021	BUY	$71.28 - $120.75 $2.59 Million - $4.4 Million	36,400 New	36,400 $94,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.